van de Donk NW - Search Results

1

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM; European Myeloma Network. van de Donk NW, et al. Haematologica. 2014 Jun;99(6):984-96. doi: 10.3324/haematol.2013.100552. Epub 2014 Mar 21. Haematologica. 2014. PMID: 24658815 Free PMC article. Review.

2

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.

de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM. de Weerdt O, et al. Among authors: van de donk nw. Neth J Med. 2001 Aug;59(2):50-6. doi: 10.1016/s0300-2977(01)00140-1. Neth J Med. 2001. PMID: 11476912 Clinical Trial.

3

Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy.

Eurelings M, Notermans NC, Van de Donk NW, Lokhorst HM. Eurelings M, et al. Among authors: van de donk nw. Muscle Nerve. 2001 Oct;24(10):1295-302. doi: 10.1002/mus.1147. Muscle Nerve. 2001. PMID: 11562908

4

Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors.

Van De Donk N, De Weerdt O, Eurelings M, Bloem A, Lokhorst H. Van De Donk N, et al. Leuk Lymphoma. 2001 Aug;42(4):609-18. doi: 10.3109/10428190109099321. Leuk Lymphoma. 2001. PMID: 11697489

5

The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells.

van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. van de Donk NW, et al. Leukemia. 2002 Jul;16(7):1362-71. doi: 10.1038/sj.leu.2402501. Leukemia. 2002. PMID: 12094262

6

Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.

van de Donk NW, Kamphuis MM, van Dijk M, Borst HP, Bloem AC, Lokhorst HM. van de Donk NW, et al. Among authors: van dijk m. Leukemia. 2003 Jan;17(1):211-9. doi: 10.1038/sj.leu.2402768. Leukemia. 2003. PMID: 12529680

7

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.

van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC. van de Donk NW, et al. Among authors: van kessel b. Blood. 2003 Nov 1;102(9):3354-62. doi: 10.1182/blood-2003-03-0970. Epub 2003 Jul 10. Blood. 2003. PMID: 12855556 Free article.

8

Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells.

van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, Lokhorst HM. van de Donk NW, et al. Among authors: van kessel b, van marion am. Clin Cancer Res. 2003 Nov 15;9(15):5735-48. Clin Cancer Res. 2003. PMID: 14654559

9

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.

Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, Cornelissen JJ, Schattenberg AV. Lokhorst HM, et al. Among authors: van oers mh, van de donk nw. Blood. 2004 Jun 1;103(11):4362-4. doi: 10.1182/blood-2003-11-3862. Epub 2004 Feb 19. Blood. 2004. PMID: 14976044 Free article.

10

G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma.

van de Donk NW, de Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel SR, Hagenbeek A, Bloem AC, Lokhorst HM. van de Donk NW, et al. Among authors: de weerdt o, van stralen e. Leukemia. 2004 Jun;18(6):1078-84. doi: 10.1038/sj.leu.2403363. Leukemia. 2004. PMID: 15085157 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page